ABSTRACT
Osteons are composed of concentric lamellar structure, the concentric lamellae are composed of periodic thin and thick sub-lamellae, and every 5 sub-lamellae is a cycle, the periodic helix angle of mineralized collagen fibers in two adjacent sub-lamellae is 30°. Four biomimetic models with different fiber helix angles were established and fabricated according to the micro-nano structure of osteon. The effects of the fiber periodic helical structure on impact characteristic and energy dissipation of multi-layer biomimetic composite were investigated. The calculation results indicated that the stress distribution, contact characteristics and fiber failur during impact, and energy dissipation of the composite are affected by the fiber helix angle. The stress concentration of composite materials under external impact can be effectively improved by adjusting the fiber helix angle when the material composition and material performance parameters are same. Compared with the sample30, the maximum stress of sample60 and sample90 increases by 38.1% and 69.8%, respectively. And the fiber failure analysis results shown that the model with a fiber helix angle of 30° has a better resist impact damage. The drop-weight test results shown that the impact damage area of the specimen with 30° helix angle is smallest among the four types of biomimetic specimens. The periodic helical structure of mineralized collagen fibers in osteon can effectively improve the impact resistance of cortical bone. The research results can provide useful guidance for the design and manufacture of high-performance, impact-resistant biomimetic composite materials.
ABSTRACT
Compared with isoalloxazine, the core chromophore of biologically important flavins, alloxazine exhibits much lower fluorescence quantum yield and larger intersystem-crossing quantum yield. However, its efficient radiationless relaxation pathways are still elusive. In this work, we have used the QM(MS-CASPT2//CASSCF)/MM method to explore the mechanistic photophysics of alloxazine chromophore in aqueous solution. On the basis of the optimized minima, conical intersections, and crossing points in the lowest (1)ππ*, (1)nπ*, (3)ππ*, and (3)nπ* states, we have proposed three energetically possible nonadiabatic relaxation pathways populating the lowest (3)ππ* triplet state from the initially populated excited (1)ππ* singlet state. The first is the direct (1)ππ*â (3)ππ* intersystem crossing via the (1)ππ*/(3)ππ* crossing point. The second is an indirect (1)ππ* â (3)ππ* intersystem crossing relayed by the dark (1)nπ* singlet state. In this route, the (1)ππ* system first decays to the (1)nπ* state via the (1)ππ*/(1)nπ* conical intersection, followed by an (1)nπ*â (3)ππ* intersystem crossing at the (1)nπ*/(3)ππ* crossing point to arrive at the final (3)ππ* state. The third is similar to the second one; but its intersystem crossing is relayed by the (3)nπ* triplet state. The (1)ππ* system first decays to the (3)nπ* state via the (1)ππ*/(3)nπ* crossing point; the generated (3)nπ* state is then de-excited to the (3)ππ* state through the (3)nπ*â (3)ππ* internal conversion at the (3)nπ*/(3)ππ* conical intersection. According to the classical El-Sayed rule, we suggest the second and third paths play a much more important role than the first one in the formation of the lowest (3)ππ* state.
ABSTRACT
BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS). DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days. RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality (risk difference=0.09; P=0.07, P for heterogeneity=0.22, I (2)=33%). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol (mean difference=-2.20; P<0.001, P for heterogeneity=0.49, I (2)=0% and mean difference=-1.71, P<0.001, P for heterogeneity=0.60, I (2)=0%). CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.
